Management of Cancer Therapeutics–Related Cardiac Dysfunction

Ajay Vallakati, Bhavana Konda, Daniel J. Lenihan, Ragavendra R. Baliga

Research output: Contribution to journalReview article

1 Scopus citations


Improvements in detection and treatment of cancer have resulted in a significant increase in cancer survivors. However, cancer survivorship comes with long-term risk of adverse effects of cancer therapies, including cardiomyopathy, heart failure, arrhythmias, ischemic heart disease, atherosclerosis, thrombosis, and hypertension. There is a renewed interest in understanding the pathophysiology of cancer therapeuticserelated cardiac dysfunction. In recent years, efforts have been directed to the management of cancer therapeuticserelated cardiac dysfunction. This article discusses the pathophysiology and molecular mechanisms that contribute to cancer therapeutics-related cardiac dysfunction and presents an napproach to the evaluation and treatment of these patients.

Original languageEnglish
Pages (from-to)553-567
Number of pages15
JournalHeart Failure Clinics
Issue number4
StatePublished - Oct 2018


  • Anthracyclines
  • Cancer therapy–mediated cardiotoxicity
  • Chemotherapy-induced cardiomyopathy
  • HER2-targeted therapies
  • Radiotherapy-induced cardiotoxicity
  • Renin-angiotensin inhibitors
  • Trastuzumab
  • β-Blockers

Fingerprint Dive into the research topics of 'Management of Cancer Therapeutics–Related Cardiac Dysfunction'. Together they form a unique fingerprint.

  • Cite this